Leiomyosarcoma clinical trials at UCSF
2 in progress, 1 open to eligible people
Leiomyosarcoma is a type of cancer that develops from smooth muscle tissue. UCSF is comparing a study drug combined with chemotherapy to a placebo combined with the same chemotherapy. The trial is for people with advanced or metastatic leiomyosarcoma who have been treated before.
ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
open to eligible people ages 18-99
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
San Francisco, California and other locations
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Sorry, in progress, not accepting new patients
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether these therapies can be safely combined and if they work better when given together in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Oakland, California and other locations
Our lead scientists for Leiomyosarcoma research studies include Varun Monga, M.D.
Last updated: